Literature DB >> 6753909

Maintenance of the antihypertensive efficacy of captopril despite consistent reduction in daily dosage.

A Mimran, B Jover.   

Abstract

1 After a period of 7 +/- 1.4 months of good control of hypertension by thrice daily administration of captopril (85 +/- 9 mg three times a day), captopril was given twice daily and the total dose was progressively reduced to sometimes very low levels in 12 patients. Twice daily administration of captopril 85 +/- 9 mg did not modify blood pressure control. 2 During reduction of captopril dosage to a minimum of 36 +/- 4 mg twice a day, the acute effect of the morning dose of captopril (last dose taken at least 12 hours before study) was assessed. Administration of the morning dose induced a decrease in mean arterial pressure from 112 +/- 4 mm Hg (104 +/- 3 mm Hg during administration of 85 +/- 9 mg) three times a day to 106 +/- 4 mm Hg, an increase in plasma renin activity, and a decrease in plasma aldosterone concentration. 3 These acute effects of captopril suggest that blood pressure was well controlled in the presence of a non-blocked circulating angiotensin-converting-enzyme activity, thus raising the possibility of alternate mechanisms by which captopril reduces arterial pressure. 4 The daily dosage of captopril needed to control hypertension may be reassessed after a certain period of good blood pressure control with 50 to 100 mg captopril three times a day.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753909      PMCID: PMC1427506          DOI: 10.1111/j.1365-2125.1982.tb02062.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

2.  Radioimmunoassay for aldosterone without chromatography. 2. Determination of plasma aldosterone.

Authors:  W Vetter; H Vetter; W Siegenthaler
Journal:  Acta Endocrinol (Copenh)       Date:  1973-11

3.  Arterial pressure responses to discontinuing antihypertensive drugs.

Authors:  H P Dustan; I H Page; R C Tarazi; E D Frohlich
Journal:  Circulation       Date:  1968-03       Impact factor: 29.690

4.  The antihypertensive effect of captopril. Evidence for an influence of kinins.

Authors:  A Mimran; R Targhetta; B Laroche
Journal:  Hypertension       Date:  1980 Nov-Dec       Impact factor: 10.190

5.  Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421.

Authors:  M L Cohen; K D Kurz
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

6.  Disposition of captopril in normal subjects.

Authors:  K J Kripalani; D N McKinstry; S M Singhvi; D A Willard; R A Vukovich; B H Migdalof
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

Review 7.  Medical intelligence drug therapy: captopril.

Authors:  D G Vidt; E L Bravo; F M Fouad
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245

8.  Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.

Authors:  B Waeber; H R Brunner; D B Brunner; A L Curtet; G A Turini; H Gavras
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

  8 in total
  2 in total

1.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Captopril in severe childhood hypertension--reversible anaemia with high dosage.

Authors:  H A Verhaaren; J Vande Walle; A Devloo-Blancquaert
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.